Margaret A. Tempero, MD, Named Editor-in-Chief of JNCCN
JNCCN – Journal of the National Comprehensive Cancer Network named Margaret A. Tempero, MD, UCSF Helen Diller Family Comprehensive Cancer Center, as the new Editor-in-Chief, succeeding Harold J. Burstein, MD, PhD, who served in the position for five years.
FORT WASHINGTON, PA – JNCCN – Journal of the National Comprehensive Cancer Network, the official journal of the National Comprehensive Cancer Network® (NCCN®),has named Margaret A. Tempero, MD, as Editor-in-Chief. Dr. Tempero will assume the position of Editor-in-Chief on February 3, 2014, succeeding Harold J. Burstein, MD, PhD, who served in the position for five years.
"NCCN is pleased to welcome Dr. Tempero as Editor-in-Chief of JNCCN," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "Dr. Tempero`s highly esteemed career and demonstration of leadership in oncology research and practice, coupled with her expansive knowledge of and experience with professional publications, make her an ideal individual to oversee the operations of JNCCN."
Dr. Tempero is Director of the UCSF Pancreas Center, and Professor of Medicine, at UCSF Helen Diller Family Comprehensive Cancer Center—one of the 23 NCCN Member Institutions. After joining UCSF in 2000, Dr. Tempero held numerous positions including, but not limited to, Deputy Director of the Cancer Center and Chief of Medical Oncology. Prior to joining the UCSF faculty, Dr. Tempero served for 17 years at the Fred and Pamela Buffett Cancer Center at the Nebraska Medical Center, where she was Deputy Director and Professor of Medicine. During that time, Dr. Tempero also served as Chief of Oncology and Hematology at Omaha V.A. Medical Center in Omaha, Nebraska.
Dr. Tempero has a long-standing history of leadership and service with NCCN. In addition to being a founding member of the NCCN Board of Directors, over the last 18 years, she has acted as Chairperson of the NCCN Guidelines Panel for Pancreatic Cancer, and, since 2003, served on the JNCCN Editorial Board. Dr. Tempero is also a long-time contributor to the NCCN Oncology Research Program (ORP), participating in Scientific Review Committees, as well as ORP working groups. Further, she is an active member of the NCCN Continuing Medical Education (CME) Advisory Committee.
Outside of her work with JNCCN, Dr. Tempero has lent her expertise as an associate editor on the editorial boards for many professional publications in internal medicine and oncology. Dr. Tempero has authored or co-authored more than 100 peer-reviewed articles, two books, and 30 book chapters. Since 1981, Dr. Tempero has spoken at more than 300 international, national, and regional conferences, meetings, and symposia. In addition, Dr. Tempero serves as an advisor for research programs at many institutions, such as The University of Texas MD Anderson Cancer Center; Mayo Clinic; University of Alabama at Birmingham Comprehensive Cancer Center; University of Arizona; University of California, Los Angeles; and the University of Chicago at Illinois, as well as for the European Organization for Research and Treatment of Cancer (EORTC). She has also served on the Oncology Drug Advisory Committee for U.S. Food and Drug Administration (FDA).
Indeed, Dr. Tempero has held numerous esteemed appointments, including President of the American Society of Clinical Oncology (ASCO) in 2003 – 2004; she is currently a member of the Board of Directors for the Association of Northern California Oncologists (ANCO), as well as a member of the Scientific Advisory Board for the Pancreatic Cancer Action Network (PanCAN) and the V Foundation. She served on the Board of Scientific Counselors for the National Cancer Institute (NCI) from 1998 – 2006, and served as Chair of Subcommittee A.
"I am honored to take on the responsibility of Editor-in-Chief for JNCCN," said Dr. Tempero. "As a founding NCCN Board member, I am very proud of how the organization has evolved and has influenced cancer care worldwide. I promise to give my best to JNCCN and to keep it on a positive trajectory."
"Harborside Press is delighted to welcome Dr. Tempero as JNCCN`s newly appointed Editor-in-Chief," said John A. Gentile, Jr., Chairman of Harborside Press and Publisher of JNCCN. "We have had the pleasure of working with Margaret since the inception of NCCN, and under her leadership and expert guidance, JNCCN will continue to flourish. We would also like to thank the past Editor-in-Chief, Dr. Harold Burstein, for his work in establishing JNCCN as one of the critical publications for oncology clinicians worldwide."
About JNCCN – Journal of the National Comprehensive Cancer Network
JNCCN`s mission is to improve the quality of cancer care by addressing oncology practice for all disease stages and presentations. Content covers the entire spectrum of oncologic health care, from prevention and screening to treatment and supportive care. JNCCN is dedicated to improving the quality of cancer care locally, nationally, and internationally while enhancing the collaboration between academic medicine and the community physician. JNCCN is further committed to disseminating information across the cancer care continuum by publishing clinical practice guidelines and reporting rigorous outcomes data collected and analyzed by experts from the world`s leading care centers. For more information about JNCCN, visit JNCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital